Nexalin Technology reconstitutes Scientific Advisory Board

Nexalin Technology (NXL) announced the reconstitution of its Scientific Advisory Board with the appointment of three renowned experts in neurology, neuroimaging, and neurodegenerative diseases. This move reflects Nexalin’s strategic prioritization of Alzheimer’s disease within its broader clinical development pipeline, supported by promising published data and internal data from studies involving its proprietary DIFS technology. Joining the SAB are Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer, each of whom brings specialized expertise that aligns with Nexalin’s Alzheimer’s-focused initiatives. The restructured SAB will play a pivotal role in guiding the Company’s scientific direction, clinical strategy, and biomarker-driven trial design for neurodegenerative and neuropsychiatric disorders. Huang is Professor of Radiology at the University of California, San Diego, Adjunct Professor in the Department of Electrical and Computer Engineering, Co-Director of the UCSD MEG Center, and a career research health scientist at the VA San Diego Healthcare System. Board certified by the American Board of Psychiatry and Neurology in both adult and pediatric neurology, as well as in brain injury medicine, Dr. Scheer has trained and held faculty positions at premier institutions including Columbia University, Cornell Medical College, Georgetown University, and the University of Pittsburgh. Dr. David Owens serves as the Company’s Chief Medical Officer and is a board-certified neuroradiologist and interventional neuroimaging specialist.